Cargando…

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

The presence of tumor-infiltrating lymphocytes in triple-negative breast cancers is correlated with improved outcomes. Ras/MAPK pathway activation is associated with significantly lower levels of tumor-infiltrating lymphocytes in triple-negative breast cancers and while MEK inhibition can promote re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dushyanthen, Sathana, Teo, Zhi Ling, Caramia, Franco, Savas, Peter, Mintoff, Christopher P., Virassamy, Balaji, Henderson, Melissa A., Luen, Stephen J., Mansour, Mariam, Kershaw, Michael H., Trapani, Joseph A., Neeson, Paul J., Salgado, Roberto, McArthur, Grant A., Balko, Justin M., Beavis, Paul A., Darcy, Phillip K., Loi, Sherene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605577/ https://www.ncbi.nlm.nih.gov/pubmed/28928458 http://dx.doi.org/10.1038/s41467-017-00728-9

Ejemplares similares

Relevance of tumor-infiltrating lymphocytes in breast cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2015)

Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
por: Wein, Lironne, et al.
Publicado: (2017)

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
por: Teo, Zhi Ling, et al.
Publicado: (2023)

Checkpoint blockade in the treatment of breast cancer: current status and future directions
por: Wein, Lironne, et al.
Publicado: (2018)

The effectiveness of HPV vaccination on the incidence of oropharyngeal cancers in men: a review
por: Macilwraith, Philip, et al.
Publicado: (2023)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

Clinical implications of prospective genomic profiling of metastatic breast cancer patients
por: van Geelen, Courtney T., et al.
Publicado: (2020)

Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
por: van Geelen, Courtney T., et al.
Publicado: (2022)

The Osteoblastic and Osteoclastic Interactions in Spinal Metastases Secondary to Prostate Cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2013)

Fostering the use of Learning Health Systems through a fellowship program for interprofessional clinicians
por: Dushyanthen, Sathana, et al.
Publicado: (2022)

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
por: Davenport, A. J., et al.
Publicado: (2018)

Designing a wholly online, multidisciplinary Master of Cancer Sciences degree
por: Lai-Kwon, Julia, et al.
Publicado: (2023)

The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE”
por: Savas, Peter, et al.
Publicado: (2016)

Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE"
por: Savas, Peter, et al.
Publicado: (2017)

Myeloma natural killer cells are exhausted and have impaired regulation of activation
por: D’Souza, Criselle, et al.
Publicado: (2021)

Virtual reality and augmented reality in radiation oncology education – A review and expert commentary
por: Kok, David L., et al.
Publicado: (2022)

Screen-based digital learning methods in radiation oncology and medical education
por: Kok, David L., et al.
Publicado: (2022)

CAR T cells take centre stage
por: Beavis, Paul A, et al.
Publicado: (2019)

Challenges of PD-L1 testing in non-small cell lung cancer and beyond
por: Wang, Minyu, et al.
Publicado: (2020)

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
por: Oliver, Amanda J., et al.
Publicado: (2018)

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020)

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
por: McArthur, Grant A.
Publicado: (2015)

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
por: Lönnstedt, Ingrid M, et al.
Publicado: (2014)

Therapeutic strategies to remodel immunologically cold tumors
por: Wang, Minyu, et al.
Publicado: (2020)

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions
por: David, Steven, et al.
Publicado: (2022)

Generating CAR T cells from tumor-infiltrating lymphocytes
por: Mills, Jane K., et al.
Publicado: (2021)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
por: Loi, Sherene
Publicado: (2013)

Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer
por: Risbridger, Gail Petuna, et al.
Publicado: (2021)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
por: Zardavas, Dimitrios, et al.
Publicado: (2014)

Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma
por: Terry, Rachael L., et al.
Publicado: (2021)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
por: Halse, H., et al.
Publicado: (2018)

TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
por: Freudenstein, Donald, et al.
Publicado: (2020)

Triple-negative breast cancer: recent treatment advances
por: Bergin, Alice R T, et al.
Publicado: (2019)

Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update()
por: Brown, Lauren C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_st29ajhqd15vtcg1jhh6j973fu